Moleculin Biotech (NASDAQ:MBRX) Earns “Buy” Rating from HC Wainwright
Moleculin Biotech (NASDAQ:MBRX – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $4.00 price objective on the stock. A number of other research analysts also recently commented on MBRX. Maxim Group raised shares […]
Moleculin Biotech (NASDAQ:MBRX – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $4.00 price objective on the stock. A number of other research analysts also recently commented on MBRX. Maxim Group raised shares […]
